Equity Insights May 31st: Synta Pharma, Arbitron, TiVo, Google, Rovi

Synta Pharmaceuticals Corp. (NASDAQ:SNTA): Jefferies believes Phase 2b lung cancer trial data expected in June could lead to significant upside in shares of Synta Pharmaceuticals and said it would be a buyer of the stock ahead of the data release. The firm keeps a Buy rating on Synta with a $7 price target.

Arbitron Inc. (NYSE:ARB): Piper Jaffray views the 14% pullback from Arbitron’s April highs as a buying opportunity and reiterates an Overweight rating on the stock with a $47 price target. Piper thinks shares at current levels are overly discounting the lack of near-term internet radio measurement revenue. The firm expects Arbitron to land a deal with Pandora once it solidifies a digital measurement solution for its broadcast clients’ online programming.

TiVo Inc. (NASDAQ:TIVO): After TiVo reported Q1 results that missed consensus, Barrington said that it still believes the company’s long-term opportunity outweighs its near-term challenges and maintains an Outperform rating on the stock. Barrington said that while TiVo’s guidance for a Q2 EBITDA loss was worse then the firm expected, management was confident in its ability to achieve break-even adjusted EBITDA for the fiscal year.

Google Inc. (NASDAQ:GOOG): Stifel Nicolaus reduced its Q2 estimates on Google to reflect the weakness of the euro. The firm’s Q2 revenue estimate is now below the consensus, and it recommends waiting for a more attractive entry point before buying Google shares. The firm maintains a Hold rating on the stock.

Rovi Corporation (NASDAQ:ROVI): Cowen said new management appears focused on execution and improved disclosure on their three core segments. The firm also cited expectations for an acceleration of service provider growth and advertising as catalysts for upside relative to the market. Shares are Outperform rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.